[go: up one dir, main page]

BRPI0814962A2 - Métodos de seleção com a utilização de receptores acoplados à proteína g e composições relacionadas. - Google Patents

Métodos de seleção com a utilização de receptores acoplados à proteína g e composições relacionadas.

Info

Publication number
BRPI0814962A2
BRPI0814962A2 BRPI0814962-3A BRPI0814962A BRPI0814962A2 BR PI0814962 A2 BRPI0814962 A2 BR PI0814962A2 BR PI0814962 A BRPI0814962 A BR PI0814962A BR PI0814962 A2 BRPI0814962 A2 BR PI0814962A2
Authority
BR
Brazil
Prior art keywords
protein coupled
coupled receptors
selection methods
related compositions
compositions
Prior art date
Application number
BRPI0814962-3A
Other languages
English (en)
Inventor
Thomas J Gardella
John T Potts
Masaru Shimizu
Fumihiko Ichikawa
Harald Juppner
Makoto Okazaki
Original Assignee
Gen Hospital Corp
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Chugai Pharmaceutical Co Ltd filed Critical Gen Hospital Corp
Publication of BRPI0814962A2 publication Critical patent/BRPI0814962A2/pt
Publication of BRPI0814962B1 publication Critical patent/BRPI0814962B1/pt
Publication of BRPI0814962B8 publication Critical patent/BRPI0814962B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/645—Secretins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
BRPI0814962A 2007-08-01 2008-08-01 métodos in vitro para determinar se um composto candidato é um agonista de longa duração ou de curta duração de um receptor acoplado à proteína g, polipeptídeo, seu uso e composição farmacêutica BRPI0814962B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US96311707P 2007-08-01 2007-08-01
US60/963,117 2007-08-01
US96308207P 2007-08-02 2007-08-02
US60/963,082 2007-08-02
US96386707P 2007-08-06 2007-08-06
US60/963,867 2007-08-06
PCT/US2008/009288 WO2009017809A2 (en) 2007-08-01 2008-08-01 Screening methods using g-protein coupled receptors and related compositions

Publications (3)

Publication Number Publication Date
BRPI0814962A2 true BRPI0814962A2 (pt) 2015-04-14
BRPI0814962B1 BRPI0814962B1 (pt) 2020-09-08
BRPI0814962B8 BRPI0814962B8 (pt) 2021-05-25

Family

ID=40305140

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814962A BRPI0814962B8 (pt) 2007-08-01 2008-08-01 métodos in vitro para determinar se um composto candidato é um agonista de longa duração ou de curta duração de um receptor acoplado à proteína g, polipeptídeo, seu uso e composição farmacêutica

Country Status (11)

Country Link
US (2) US8568737B2 (pt)
EP (2) EP2187902B1 (pt)
JP (1) JP5711966B2 (pt)
KR (1) KR101661730B1 (pt)
CN (2) CN101784281B (pt)
AU (1) AU2008282805B2 (pt)
BR (1) BRPI0814962B8 (pt)
CA (2) CA2694667C (pt)
MX (2) MX353986B (pt)
RU (1) RU2506274C2 (pt)
WO (1) WO2009017809A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101661730B1 (ko) 2007-08-01 2016-10-04 더 제너럴 하스피탈 코포레이션 Ｇ―단백질 결합 수용체를 이용한 스크리닝 방법 및 관련 조성물
EP2411038B1 (en) * 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
EA022212B1 (ru) * 2009-04-24 2015-11-30 Кадила Хелзкэр Лимитед Короткоцепочечные пептиды в качестве агониста рецептора паратиреоидного гормона (pth)
EP2569003B1 (en) * 2010-05-13 2017-10-25 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
WO2012158962A2 (en) * 2011-05-18 2012-11-22 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2015037764A1 (ko) * 2013-09-16 2015-03-19 서울대학교 산학협력단 Gpcr19 경로의 활성화에 의한 골수 유래 면역 조절 세포 및 면역 조절 b 림프구의 체내외 증폭
US20170283844A1 (en) * 2014-09-11 2017-10-05 The State of Israel, Ministry of Agriculture & Rural Development, Argricultural Research Organiza Methods of producing mogrosides and compositions comprising same and uses thereof
US20190119348A1 (en) * 2016-04-01 2019-04-25 The General Hospital Corporation Parathyroid hormone receptor 1 antagonist and inverse agonist polypeptides and methods of their use
CN106267162A (zh) * 2016-08-25 2017-01-04 浙江省新华医院 促胰液素在制备治疗骨质疏松症药物中的用途
JP2021516222A (ja) 2018-03-16 2021-07-01 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモンポリペプチドコンジュゲートおよびその使用方法
US11298701B2 (en) 2018-11-26 2022-04-12 King Instrumentation Technologies Microtiter plate mixing control system
FR3092115B1 (fr) * 2019-01-30 2021-11-12 Cisbio Bioassays analogues de GTP fluorescents et utilisation
KR102264116B1 (ko) * 2019-06-19 2021-06-14 한국과학기술연구원 세포 소포체 내 g-단백질 연결 수용체(gpcr)의 실시간 활성 상태 분석 방법 및 컴퓨터 프로그램
CN112111003B (zh) * 2019-06-20 2022-02-11 中国农业大学 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS5896052A (ja) 1981-11-30 1983-06-07 Toyo Jozo Co Ltd 高活性ｈ−ＰＴＨ（１−３４）アミドの製造法
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4518526A (en) 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
JPS59204159A (ja) 1983-04-28 1984-11-19 Toyo Jozo Co Ltd 〔Ｍｅｔ（Ｏ）↑８’↑１↑８〕ｈＰＴＨ−（１−３４）ペプチド
JPS60201244A (ja) 1984-03-26 1985-10-11 Ricoh Co Ltd 湿度センサ
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
US5010010A (en) 1986-10-22 1991-04-23 Selmer-Sande, A.S. Production of human parathyroid hormone from microorganisms
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
US5527772A (en) 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
US5605815A (en) 1988-03-14 1997-02-25 Yale University Nucleic acids encoding and expression of parathyroid hormone-like peptide
DE68921665T2 (de) 1988-05-09 1995-09-21 Merck & Co Inc Hemmer vom flüssigen kalziumerhöhenden Faktor.
US5217896A (en) 1988-12-30 1993-06-08 Oncogene Science, Inc. Monoclonal antibodies recognizing parathyroid hormone-like protein
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
AU6448990A (en) 1989-09-29 1991-04-28 Her Majesty in Right of Canada, as represented by National Research Council Canada Synthesis of mature human parathyroid hormone
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
ES2090297T5 (es) 1989-11-06 2005-03-01 Cell Genesys, Inc. Produccion de proteinas que utilizan recombinacion homologa.
IT1238348B (it) 1989-11-16 1993-07-13 Processo per la preparazione di costrutti genetici per l'espressione del fattore di crescita nervoso in cellule eucariote.
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5648270A (en) 1995-02-06 1997-07-15 Molecular Probes, Inc. Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
US5326692B1 (en) 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5453517A (en) 1992-02-25 1995-09-26 Molecular Probes, Inc. Reactive derivatives of bapta used to make ion-selective chelators
US5405975A (en) 1993-03-29 1995-04-11 Molecular Probes, Inc. Fluorescent ion-selective diaryldiaza crown ether conjugates
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5459276A (en) 1994-05-20 1995-10-17 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators for heavy metals
US5266490A (en) 1991-03-28 1993-11-30 Regeneron Pharmaceuticals, Inc. Mammalian expression vector
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
JPH0532696A (ja) 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
US7150974B1 (en) 1991-04-05 2006-12-19 The General Hospital Corporation Parathyroid hormone receptor binding method
US7132260B2 (en) 1991-04-05 2006-11-07 The General Hospital Corporation DNA encoding parathyroid hormone receptor
US5261686A (en) 1992-04-06 1993-11-16 Buckler Clive E Semi-recumbent
JP3464796B2 (ja) 1991-04-05 2003-11-10 ザ ジェネラル ホスピタル コーポレーション 副甲状腺ホルモンのレセプターとそれをコードしているｄｎａ
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
ATE148889T1 (de) 1991-09-18 1997-02-15 Affymax Tech Nv Verfahren zur synthese der verschiedenen sammlungen von oligomeren
WO1993006846A1 (en) 1991-10-10 1993-04-15 Pang Peter K T Parathyroid hormone analogues and use in osteoporosis treatment
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
DE4138621A1 (de) 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
SK74594A3 (en) 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5382658A (en) 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
IT1255723B (it) 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5871486A (en) 1993-01-21 1999-02-16 Acumed, Inc. Variable pitch bone screw
EP0705334A1 (en) 1993-06-14 1996-04-10 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
WO1995002610A1 (en) 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5496801A (en) 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
CA2126132A1 (en) 1994-06-17 1995-12-18 Witold Neugebauer Peptide synthesis on chitosan
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
US5836905A (en) 1994-06-20 1998-11-17 Lemelson; Jerome H. Apparatus and methods for gene therapy
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
DE4434551A1 (de) 1994-09-28 1996-04-04 Forssmann Wolf Georg Prof Dr D Peptide aus der Sequenz des hPTH (1-37)
PL321094A1 (en) 1994-12-22 1997-11-24 Astra Ab Parathyroid hormone (pth) containing preparation administered by inhalation
US5717062A (en) 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
JPH09157294A (ja) 1995-06-15 1997-06-17 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
CA2178894A1 (en) 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
RU2157699C2 (ru) * 1996-03-29 2000-10-20 Биомежер Инкорпорэйтед Пептиды, обладающие сродством к рецептору паратгормона (ртн) и стимулирующие активность аденилатциклазы
ES2248853T3 (es) * 1996-07-31 2006-03-16 The General Hospital Corporation Nuevos analogos del peptido relacionado con la hormona paratiroidea.
NZ333809A (en) 1996-08-02 2000-07-28 Ca Nat Research Council Parathyroid hormone analogues for use as medicaments in treating osteoporosis
US5917123A (en) 1997-03-14 1999-06-29 University Of Pittsburgh Transgenic mice containing a nucleic acid encoding tumor necrosis factor-α under the control of a cardiac specific regulatory region
US6183974B1 (en) 1997-07-31 2001-02-06 The General Hospital Corporation Screening assays for G protein coupled receptor agonists and antagonists
CA2306344A1 (en) 1997-10-14 1999-04-22 Masahiko Sato Method of building and maintaining bone
ATE392431T1 (de) * 1998-05-05 2008-05-15 Sod Conseils Rech Applic Pth2 rezeptor selektive verbindungen
JP4486256B2 (ja) 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
DE69938064T2 (de) 1998-11-25 2009-01-15 The General Hospital Corp., Boston Aminoterminal modifizierte parathyroidhormon (pth) analoge
ATE458054T1 (de) 1998-11-25 2010-03-15 Gen Hospital Corp Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
AU4217299A (en) 1998-11-30 2000-06-19 General Hospital Corporation, The Pth1r and pth3r receptors, methods and uses thereof
US7057012B1 (en) 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
EP1612263A1 (en) 1998-12-31 2006-01-04 The General Hospital Corporation PTH receptor and screening assay utilizing the same
EP1147133B1 (en) 1998-12-31 2008-08-06 The General Hospital Corporation Peptides consisting of two PTH functional domains fused by a linker molecule, and derivatives thereof
EP1222208B1 (en) 1999-09-29 2008-10-29 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
AU7734800A (en) 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
US7022815B1 (en) * 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US6838264B2 (en) 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
WO2002068585A2 (en) 2001-01-17 2002-09-06 The General Hospital Corporation Tip39 polypeptides
JP4837888B2 (ja) 2001-07-23 2011-12-14 ザ ジェネラル ホスピタル コーポレイション コンホメーションが拘束された副甲状腺ホルモン（ｐｔｈ）類似体
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
JP4541899B2 (ja) 2003-01-24 2010-09-08 ザ ジェネラル ホスピタル コーポレイション ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン（ｐｔｈ）アナログ
WO2004093902A1 (en) 2003-03-19 2004-11-04 The General Hospital Corporation CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS
US7910544B2 (en) 2003-07-17 2011-03-22 The General Hospital Corporation Conformationally constrained parthyroid hormone (PTH) analogs
CA2504920C (en) * 2004-05-14 2014-04-01 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof
EP1799240A4 (en) 2004-09-16 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES USING SKELETAL ANABOLIC DRUGS
JP2009545320A (ja) 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
KR101661730B1 (ko) 2007-08-01 2016-10-04 더 제너럴 하스피탈 코포레이션 Ｇ―단백질 결합 수용체를 이용한 스크리닝 방법 및 관련 조성물

Also Published As

Publication number Publication date
CN101784281B (zh) 2014-07-02
WO2009017809A3 (en) 2009-04-30
EP2650009A2 (en) 2013-10-16
RU2506274C2 (ru) 2014-02-10
US20140086842A1 (en) 2014-03-27
EP2650009B1 (en) 2018-02-21
RU2010107292A (ru) 2011-09-10
AU2008282805B2 (en) 2014-05-01
EP2650009A3 (en) 2014-01-29
EP2187902A2 (en) 2010-05-26
HK1201849A1 (en) 2015-09-11
CA2694667C (en) 2018-10-30
CA2694667A1 (en) 2009-02-05
WO2009017809A2 (en) 2009-02-05
US20110172153A1 (en) 2011-07-14
JP5711966B2 (ja) 2015-05-07
EP2187902A4 (en) 2010-10-27
CA3017668C (en) 2021-11-09
MX2010001183A (es) 2010-04-21
MX353986B (es) 2017-11-06
KR20100090238A (ko) 2010-08-13
CN104072606A (zh) 2014-10-01
KR101661730B1 (ko) 2016-10-04
CN101784281A (zh) 2010-07-21
EP2650009B8 (en) 2018-07-18
US8568737B2 (en) 2013-10-29
EP2187902B1 (en) 2013-04-17
BRPI0814962B1 (pt) 2020-09-08
AU2008282805A1 (en) 2009-02-05
CN104072606B (zh) 2017-09-22
BRPI0814962B8 (pt) 2021-05-25
US9057727B2 (en) 2015-06-16
JP2010536327A (ja) 2010-12-02
MX346714B (es) 2017-03-24
CA3017668A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
BRPI0814962A2 (pt) Métodos de seleção com a utilização de receptores acoplados à proteína g e composições relacionadas.
CY2018001I1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα a il-17
PT2123158E (pt) Composição herbicida
AR062844A1 (es) Composicion pesticida
ITMI20062368A1 (it) Composizioni erbicide
EP2151236A4 (en) G-PROTEIN-CONJUGATED RECEPTOR AGONIST
EP2215246A4 (en) PROTEIN SCAFFOLDS
DK2046826T3 (da) Exendin-fusionsproteiner
HRP20151108T1 (xx) Antagonisti nogo-receptora
DK1965646T3 (da) Herbicid sammensætning
DK3118220T3 (da) Protein
DE602006003113D1 (de) Aiguille à ponction guidee ultrasoniquement
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
EP1959959A4 (en) MORPHOLIN-CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS
DK2035736T3 (da) Muffeforbindelse
BRPI0811551A2 (pt) Articulação de quatro pontos
BRPI0814971A2 (pt) Proteína
EP1912680A4 (en) HER-2 PEPTIDE
DE502005005266D1 (de) Dosierpumpe
EP2023100A4 (en) COMBINATION SCALES
DE502005004671D1 (de) Polyamid-EVA Mischungen
DE602007011353D1 (de) Netzwerkauswahl
DK2100540T3 (da) Ergonomisk sæde
DE602007009260D1 (de) Zwischenhülse
FR2907178B1 (fr) Joint homocinetique

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF